Vita

Prof. Dr. Carsten Saft

Oberarzt

Neurologie

0234/509-6405

 

Neurologische Klinik, Ruhruniversity
St. Josef- und St. Elisabeth- Hospital gGmbH
Huntington-Center NRW
Research department “Neurodegeneration”

Telefon 0234/509-2703

Gudrunstrasse 56
44791 Bochum

Telefon 0234/509-6405
carsten.saft@ruhr-uni-bochum.de

General information

Date of Birth: 26.10.1965
Married, one daughter
Current pos.: Head of the Huntington Center North Rhine-Westphalia (NRW, clinical part), Assistant medical director for movement disorders

Academic education with degree

02/2013 Professor of Neurology (APL), Department of Neurology, Ruhr-University Bochum
01/2007 Habilitation/Venia Legendi (Neurology) – Faculty of Medicine, Ruhr-University Bochum
11/2004 Board Certification in Neurology
1988-1996 Medical School, University of Mainz and Münster, Germany; Philadelphia, USA

 

Professional career

02/2007 W2 - foundation professorship “Neurogenetik” Teva Pharma GmbH, 3 years (225.000 € total)
07/2006 Head of the Huntington Center North Rhine-Westphalia (NRW, clinical part), Assistant medical director for movement disorders
05/2003-04/2004 Resident at the Department of Psychiatry, Westfälische-Wilhelms University, Münster
04/2002-04/2003 Project manager “Neurowissenschaften/ multiple Sklerose”, Gemeinnützige Hertie-Stiftung (Foundation), Frankfurt am Main
01/1997 Resident at the Department of Neurology, St. Josef Hospital, Ruhr-University Bochum
08/1996-11/1996 Resident at the Institute of Experimental Epilepsy Research, Westfälische Wilhelms-Universität, Münster

 

Other

2017 / 2018 Chair, "Scientific and Bioethics Advisory Committee (SBAC)" of the European Huntington Disease Network
2014 / 2019 Elected Member of the "Scientific and Bioethics Advisory Committee (SBAC)" of the European Huntington Disease Network, 2016 Co-Chair
2014 steering committee, HD Training Platform (CHDI)
2013 / 2018 steering committee “REGISTRY”, study of the European Huntington´s Disease Network (EHDN).
2014 Department representative for hygiene
2013 Department representative for ethical questions
2013 Genetic counseling for Neurology §7 Abs. 3 GenDG
2013 steering committee, Deep Brain Stimulation (DBS) of the Globus pallidus (GP) in HD: A prospective, randomizied, controlled multi-centre study.
2010 / 2016 Lead author of the Guidelines Committee “Huntington's Disease / Chorea” of the German Society of Neurology
12/2006 Pfizer-Research Award
12/1997 Award of the University Münster for doctoral thesis “Antiepileptic effects of cobalt, manganese and magnesium on bicuculline-induced epileptiform activity in hippocampal neurons”; note: summa com laude

 

Research interest: Huntington’s disease (Treatment, Biomarker), Movement disorders

Journal Editor:

  • International Editorial Review Board - Journal of Epidemiological Research
  • Editorial board of the Journal of Huntington's Disease

 

Sub-Investigator / Independent rater / Co-PI: Included (n) Start/End Eudra-CT/NCT
Ropinirole in Parkinson’s Disease, Phase III ~5 1997/1998  
Pramipexole Eye Safety Study in Parkinson’s Disease, Phase III ~3 1998/2000  
Riluzole in Parkinson’s Disease / Lab-Monitor, Phase III   ~1 2002/2004 54274x-321
Budipine in Parkinson’s Disease, Phase III    ~2 1997/1999 NCT00013624
Riluzole in Huntington’s Disease, Phase III 60 1999/2004 NCT00277602
Amaril, Ethyl-EPA in Huntington’s Disease (HD), Phase III  6 2006/2007 2005-002088-98
Latrepirdine in Huntington’s Disease (HD), Phase III HORIZON 15 2009/2011 2009-011800-44
      NCT00920946
Latrepirdine in Huntington’s Disease (HD), Phase III HORIZON Plus  15 2010/2011 2009-018123-32
EURO-HD, Registry-Natural History Study in Huntington’s Disease (HD) 361 2004/2009 NCT01590589
Pilot - Deep Brain Stimulation of the Globus Pallidus; Referral Neurologist 3 2009/2012 NCT00902889
Deep Brain Stimulation of the Globus Pallidus in HD; Referral Neurologist 4 2015 NCT02535884
IPSEN PHARMA S.A.S; Phase IIa in Huntington’s Disease; Referral Neurologist1 1 2015/2016 2013-002899-41
      NCT02231580
Civitas CVT 301-005 in Parkinson’s disease (2. Rater), Phase III 6 2015/2017 2014-003799-22
Brexpiprazole, Agitation Associated with Alzheimer's Disease, Phase III 2 2015/2017 2013-000504-41
      NCT01862640
Brexpiprazole in Alzheimer’s disease / Open Follow up 1 2016/2018 2013-000424-23
      NCT01922258
Intrathecally ISIS 814907 in Mild Alzheimer’s Disease (Co-PI); Phase I/II 1 2017 2016-002713-22
      NCT03186989
Principle-Investigator: Included (n)  Start/End Eudra-CT/NCT
Neurosearch, ACR-16 in HD, MERMAID, Phase III 16 2008/2009 2007-004988-22
      NCT00665223
Novartis Huntington Study, AFQ056 reducing corea, Phase II 8 2009/2011 2009-011743-39
      NCT01019473
EURO-HD, Registry-Natural History Study in Huntington’s Disease (HD) 361 2009/2018 NCT01590589
EURO-HD, Registry - Lifestyle Substudie 9 2011/2014 NCT01590589
EURO-HD, Registry - Juvenile Substudie 4 2011/2014 NCT01590602
EURO-HD, Registry - Irritability Substudie 8 2011/2014 NCT01590589
EURO-HD, Registry - Frsbe Substudie 4 2011/2014 NCT01590589
EURO-HD, Registry - QoL Substudie 18 2011/2018 NCT01590589
Mito-NET Natural History Study, Mitochondriopathy 2 2010/2015 RD ID # 248334
Paddingtion, SEN 0014196 in Huntington’s Disease, Phase 1b 5 2011/2012 2010–021563-32
      NCT01485952
ETON, Epigallocatechin in Huntington’s Disease HD (IIT J Priller Charité), P II 5 2011/2014 2010-023941-31
      NCT01357681
Action HD, Bupoprion in Huntington’s Disease (IIT J Priller Charité), Phase III 14 2011/2014 2009-013698-16
SEN 0014196 in Huntington’s Disease (NeuroSearch), Phase IIa 17 2011/2013 2011-001131-32
      NCT01521585
ENROLL-HD (Natural History Study in Huntington’s Disease) >770 2014 NCT01574053
HDClarity CSF Biomarker in HD           >30 2017 NCT02855476
PRIDE-HD, TEVA, Pridopidine in Huntington’s Disease; Phase II 10 2014/2017 2013-001888-23
      NCT02006472
PRIDE-HD OPEN Follow up 9 2016/2017 2015-000904-24
      NCT02494778
Pfizer PDE10, PF- A8241021 in Huntington’s Disease Phase II 14 2015/2017 2014-001291-56
Pfizer PDE10, PF- A8241022 Extension in Huntington’s Disease Phase II 9 2016/2018 2014-004900-31
      NCT02342548
LEGATO, TEVA (Laquinimod in Huntington’s Disease) Phase II 11 2015/2018 2014-000418-75
IONIS HTTRx CS1 Antisense in early Huntington’s Disease. Phase I/IIa 7 2015/2017 2015-000381-66
      NCT02519036
IONIS HTTRx CS2 OLE Antisense in early Huntington’s Disease, Phase II 7 2018 2017-002471-25
      NCT03342053
Roche Natural History Study, BN40422 9 2019 NCT03664804
Roche BN40955 (ISIS443139-CS2) Antisense in Huntington’s Disease; OLE   In Preparation 2017-002471-25
      NCT03842969
Roche BN40423 (ISIS443139-CS2) Antisense in Huntington’s Disease, Phase III   In Preparation  

 

H-Index: 35
Cumulative Impact factor:  ~793.7

10 most important publications within the last 5 years

  1. Hoffmann R, Stüwe SH, Goetze O, Banasch M, Klotz P, Lukas C, Tegenthoff M, Beste C, Orth M, Saft C.; Progressive hepatic mitochondrial dysfunction in premanifest Huntington's disease. Mov Disord. 2014 May;29(6):831-4.

  2. Beste C, Stock AK, Ness V, Hoffmann R, Saft C.; Evidence for divergent effects of neurodegeneration in Huntington's disease on attentional selection and neural plasticity: implications for excitotoxicity. Brain Struct Funct. 2015 May;220(3):1437-47.

  3. Matusch A*, Saft C*, Elmenhorst D, Kraus PH, Gold R, Hartung HP, Bauer A.; Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease. *contributed equally
    Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1210-20.

  4. Skodda S, Schlegel U, Hoffmann R, Saft C.; Impaired motor speech performance in Huntington's disease. J Neural Transm. 2014 Apr;121(4):399-407.

  5. Saft C.; What is the Course of Huntington's Disease. Comment, The Lancet Neurology; Volume 13, Issue 12, Pages 1165 - 1166, December 2014

  6. Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ.; Treating the whole body in Huntington’s Disease. Lancet Neurology 2015 Nov;14(11):1135-42

  7. Skodda S, Grönheit W, Lukas C, Bellenberg B, von Hein SM, Hoffmann R, Saft C; Two different phenomena in basic motor speech performance in premanifest Huntington Disease. Neurology April 05, 2016; 86 (14)

  8. Saft C; Identifying modifiers of Huntington's disease progression. Comment. Lancet Neurol. 2017 Jun 19. pii: S1474-4422(17)30179-5.

  9. van Well EM, Bader V, Patra M, Sánchez-Vicente A, Meschede J, Furthmann N, Schnack C, Blusch A, Longworth J, Petrasch-Parwez E, Mori K, Arzberger T, Trümbach D, Angersbach L, Showkat C, Sehr DA, Berlemann LA, Goldmann P, Clement AM, Behl C, Woerner AC, Saft C, Wurst W, Haass C, Ellrichmann G, Gold R, Dittmar G, Hipp MS, Hartl FU, Tatzelt J, Winklhofer KF. A protein quality control pathway regulated by linear ubiquitination. EMBO J. 2019 May 2;38(9).

  10. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM; Targeting Huntingtin Expression in Patients with Huntington’s Disease. N Engl J Med, 2019, May 6. NEJM.org

Publikationsliste

Medline listed:

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM; Targeting Huntingtin Expression in Patients with Huntington’s Disease. New England Journal of Medicine in press
(IF 79.258)

van Well EM, Bader V, Patra M, Sánchez-Vicente A, Meschede J, Furthmann N, Schnack C, Blusch A, Longworth J, Petrasch-Parwez E, Mori K, Arzberger T, Trümbach D, Angersbach L, Showkat C, Sehr DA, Berlemann LA, Goldmann P, Clement AM, Behl C, Woerner AC, Saft C, Wurst W, Haass C, Ellrichmann G, Gold R, Dittmar G, Hipp MS, Hartl FU, Tatzelt J, Winklhofer KF. A protein quality control pathway regulated by linear ubiquitination. EMBO J. 2019 May 2;38(9).
(IF 10.7)

Quarrell OWJ, Nance MA, Nopoulos P, Reilmann R, Oosterloo M, Tabrizi SJ, Furby H, Saft C, Roos RAC, Landwehrmeyer BH, Burgunder JM, On behalf of the Juvenile Huntington’s Disease Working Group of the European Huntington Disease Network; Defining Pediatric Huntington’s Disease: Time to abandon the term juvenile Huntington’s disease? Mov Disord. 2019 Apr;34(4):584-585.
(IF 7.072)

Oosterloo M, Bijlsma EK, van Kuijk SM, Minkels F, de Die-Smulders CE; REGISTRY Investigators of the European Huntington's Disease Network; Registry Steering committee; Language coordinators; EHDN's associate site in Singapore.(Collaborator) Clinical and genetic characteristics of late-onset Huntington's disease. Parkinsonism Relat Disord. 2018 Nov 29. pii: S1353-8020(18)30490-5.
(IF 4.721)

Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators. (Collaborator) Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2018 Dec 14. pii: S1474-4422(18)30391-0.
(IF 26.284)

McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D, Holmans P, Jones L; REGISTRY Investigators of the European Huntington's Disease Network. Collaborator Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study. J Huntingtons Dis. 2018;7(3):209-222.
(IF )

Dogan I, Romanzetti S, Didszun C, Mirzazade S, Timmann D, Saft C, Schöls L, Synofzik M, Giordano IA, Klockgether T, Schulz JB, Reetz K. Structural characteristics of the central nervous system in Friedreich ataxia: an in vivo spinal cord and brain MRI study. J Neurol Neurosurg Psychiatry. 2018 Jun 26.
(IF 7.349)

Valcárcel-Ocete L, Fullaondo A, Alkorta-Aranburu G, García-Barcina M, Roos RAC, Hjermind LE, Saft C, Frontali M, Reilmann R, Rickards H; REGISTRY investigators of the European Huntington’s Disease Network (EHDN), Zubiaga AM, Aguirre A. Does arterial hypertension influence the onset of Huntington's disease? PLoS One. 2018 May 23;13(5):e0197975.
(IF 2.806)

Ferrea S, Groiss SJ, Elben S, Hartmann CJ, Dunnett SB, Rosser A, Saft C, Schnitzler A, Vesper J, Wojtecki L; Surgical Approaches Working Group of the European Huntington’s Disease Network (EHDN). Pallidal deep brain stimulation in juvenile Huntington's disease: local field potential oscillations and clinical data. J Neurol. 2018 May 3. doi: 10.1007/s00415-018-8880-1. [Epub ahead of print]
(IF 3.389)

Beckmann H, Bohlen S, Saft C, Hoffmann R, Gerss J, Muratori L, Ringelstein EB, Landwehrmeyer GB, Reilmann R. Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study. Gait Posture. 2018 May;62:451-457
(IF 2.347)

Saft C, von Hein SM, Lücke T, Thiels C, Peball M, Djamshidian A, Heim B, Seppi K. Cannabinoids for Treatment of Dystonia in Huntington's Disease. J Huntingtons Dis. 2018 Mar 16. doi: 10.3233/JHD-170283. [Epub ahead of print]
(IF )

Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease. Fatoba O, Kloster E, Reick C, Saft C, Gold R, Epplen JT, Arning L, Ellrichmann G. Exp Neurol. 2018 Apr;302:112-128.
(IF 4.706)

Saft C Identifying modifiers of Huntington's disease progression. Lancet Neurol. 2017 Jun 19. pii: S1474-4422(17)30179-5.
(IF 26.284)

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ. (Contributor) Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurol. 2017 Jun 20. pii: S1474-4422(17)30161-8.
(IF 26.284)

Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Sci Rep. 2019 Mar 15;9(1):4960. Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden M, Sehr D, Winklhofer K, Saft C, Gold R Laquinimod treatment in the R6/2 mouse model. Sci Rep. 2017 Jul 10;7(1):4947.
(IF 4.259)

Gelderblom H, Wüstenberg T, McLean T, Mütze L, Fischer W, Saft C, Hoffmann R, Süssmuth S, Schlattmann P, van Duijn, E, Landwehrmeyer B, Priller J Buprorion for the treatment of apathy in Huntington’s disease: A multicenter, randomised double-blind, placebo-controlled, prospective crossover trial. Plos one D-16-27768R3
(IF 2.806)

Ibisler A, Ocklenburg S, Stemmler S, Arning L, Epplen JT, Saft C*, Hoffjan S Prospective Evaluation of Predictive DNA Testing for Huntington`s Disease in a German Centre *contributed equally J Genet Couns. 2017 Oct;26(5):1029-1040.
(IF 1.938)

Wilhelms W, Bellenberg B, Köster O, Weiler F, Hoffmann R, Gold R, Saft C*, Lukas C. Progressive spinal cord atrophy in manifest and premanifest Huntington's disease. J Neurol Neurosurg Psychiatry. 2017 Feb 16. pii: jnnp-2016-315000. (IF 7.349) *contributed equally

Vogel AP, Churchyard A, Stout J, Saft CTwo different phenomena in basic motor speech performance in premanifest Huntington disease. Neurology. 2016 Nov 22;87(21):2283.
(IF 8.32)

Reick C, Ellrichmann G, Tsai T, Lee DH, Wiese S, Gold R, Saft C, Linker RA. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease. Exp Neurol. 2016 Nov;285(Pt A):12-23.
(IF 4.706)

Jacobs M, Hart EP, van Zwet EW, Bentivoglio AR, Burgunder JM, Craufurd D, Reilmann R, Saft C, Roos RA; REGISTRY investigators of the European Huntington’s Disease Network. Progression of motor subtypes in Huntington's disease: a 6-year follow-up study. J Neurol. 2016 Oct;263(10):2080-5.
(IF 3.389)

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network..Clinical manifestations of intermediate allele carriers in Huntington disease. Neurology. 2016 Aug 9;87(6):571-8.
(IF 8.32)

Skodda S, Grönheit W, Lukas C, Bellenberg B, von Hein SM, Hoffmann R, SaftTwo different phenomena in basic motor speech performance in premanifest Huntington Disease. Neurology April 05, 2016; 86 (14)
(IF 8.32)

Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ; Treating the whole body in Huntington’s Disease. Lancet Neurol. 2015 Nov;14(11):1135-42.
(IF 26.284)

Wojtecki L, Groiss SJ, Ferrea S, Elben S, Hartmann CJ, Dunnett SB, Rosser A, Saft C, Südmeyer M, Ohmann C, Schnitzler A, Vesper J; Surgical Approaches Working A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington's Disease. Group of the European Huntington’s Disease Network (EHDN). Front Neurol. 2015 Aug 18;6:177.
(IF 3.552)

Saft C; What is the Course of Huntington's Disease. Comment, Lancet Neurol. 2014 Dec;13(12):1165-6.
(IF 26.284)

Valcárcel-Ocete L, Alkorta-Aranburu G, Iriondo M, Fullaondo A, García-Barcina M, Fernández-García JM, Lezcano-García E, Losada-Domingo JM, Ruiz-Ojeda J, Álvarez de Arcaya A, Pérez-Ramos JM, Roos RA, Nielsen JE, Saft C; REGISTRY investigators of the European Huntington's Disease Network, Zubiaga AM, Aguirre A. Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene. PLoS One. 2015 Jul;10(7):e0131573.
(IF 2.806)

Reilmann R, Rouzade-Dominguez ML, Saft C, Süssmuth SD, Priller J, Rosser A, Rickards H, Schöls L, Pezous N, Gasparini F, Johns D, Landwehrmeyer GB, Gomez-Mancilla B.; A Randomized, Placebo-Controlled Trial of AFQ056 for the Treatment of Chorea in Huntington's Disease. Mov Disord. 2015 Mar;30(3):427-31.
(IF 7.072)

Saft C, Hoffmann R, Strassburger-Krogias K, Lücke T, Meves SH, Ellrichmann G, Krogias C. Echogenicity of basal ganglia structures in different Huntington's disease phenotypes. J Neural Transm. 2015 Jun;122(6):825-33.
(IF 2.392)

Rusz J*, Saft C*, Schlegel U, Hoffman R, Skodda S; Phonatory Dysfunction as a Potential State Biomarker in Premanifest Huntington Disease
PLoS One. 2014 Nov 19;9(11):e113412                                          *contributed equally
(IF 2.806)

Lee DH, Heidecke H, Schröder A, Paul F, Wachter R, Hoffmann R, Ellrichmann G, Dragun D, Waschbisch A, Stegbauer J, Klotz P, Gold R, Dechend R, Müller DN, Saft C*, Linker RA*; Detection of angiotensin II type 1 receptor auto-antibodies in Huntington´s disease. Mol Neurodegener. 2014 Nov 15;9:49. *contributed equally
(IF 6.78)

Saft C, Siglienti I, Gold R, Schlamann M, Hindy NE, Sure U, Forsting M. High noon back pain- severe pseudoradicular pain as a lead symptom of superficial siderosis: a case report. Ther Adv Neurol Disord. 2014 Nov;7(6):276-8.
(IF 4.192)

Süssmuth SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G, Andersen CA, Di Bacco M, Lamanna C, Diodato E, Massai L, Diamanti D, Mori E, Magnoni L, Dreyhaupt J, Schiefele K, Craufurd D, Saft C, Rudzinska M, Ryglewicz D, Orth M, Brzozy S, Baran A, Pollio G, Andre R, Tabrizi SJ, Darpo B, Westerberg G; PADDINGTON Consortium. An Exploratory Double blind, Randomised Clinical Trial with Selisistat, a SirT1 Inhibitor, in Patients with Huntington's Disease. Br J Clin Pharmacol. 2015 Mar;79(3):465-76.
(IF 3.493)

Ness V, Bestgen AK, Saft C, Beste C. Changes in cognitive control in pre-manifest Huntington's disease examined using pre-saccadic EEG potentials - a longitudinal study. J Huntingtons Dis. 2014;3(1):33-43.
(IF )

Beste C, Humphries M, Saft C. Striatal disorders dissociate mechanisms of enhanced and impaired response selection – Evidence from cognitive neurophysiology and computational modelling. Neuroimage Clin. 2014 Apr 12;4:623-34.
(IF 4.348)

Beste C, Mückschel M, Elben S, J Hartmann C, C McIntyre C, Saft C, Vesper J, Schnitzler A, Wojtecki L. Behavioral and neurophysiological evidence for the enhancement of cognitive control under dorsal pallidal deep brain stimulation in Huntington's disease. Brain Struct Funct. 2015 Jul;220(4):2441-8.
(IF 4.698)

Beste C, Saft C. Benign hereditary chorea as an experimental model to investigate the role of medium spiny neurons for response adaptation. Neuropsychologia. 2014 Jul;59:124-9.
(IF 3.197)

Reick C, Ellrichmann G, Thöne J, Scannevin RH, Saft C, Linker RA, Gold R. Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation. Exp Neurol. 2014 Jul;257:50-6.
(IF 4.706)

Hoffmann R, Stüwe SH, Goetze O, Banasch M, Klotz P, Lukas C, Tegenthoff M, Beste C, Orth M, Saft C. Progressive hepatic mitochondrial dysfunction in premanifest Huntington's disease. Mov Disord. 2014 May;29(6):831-4.
(IF 7.072)

Beste C, Stock AK, Ness V, Hoffmann R, Saft C. Evidence for divergent effects of neurodegeneration in Huntington's disease on attentional selection and neural plasticity: implications for excitotoxicity. Brain Struct Funct. 2015 May;220(3):1437-47.
(IF 4.698)

Matusch A, Saft C, Elmenhorst D, Kraus PH, Gold R, Hartung HP, Bauer A. Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease.  *contributed equally Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1210-20.
(IF 7.277)

Skodda S, Schlegel U, Hoffmann R, Saft CImpaired motor speech performance in Huntington's disease. J Neural Transm. 2014 Apr;121(4):399-407.
(IF 2.392)

Saft C, Andrich JE, Müller T, Becker J, Jackowski J. Oral and dental health in Huntington's disease - an observational study. BMC Neurol. 2013 Sep 3;13:114.
(IF 2.006)

Beste C, Saft C. Action selection in a possible model of striatal medium spiny neuron dysfunction: behavioral and EEG data in a patient with benign hereditary chorea. Brain Struct Funct. 2015 Jan;220(1):221-8.
(IF 4.698)

Kloster E, Saft C, Akkad DA, Epplen JT, Arning L. Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R. J Mol Med (Berl). 2014 Feb;92(2):177-84.
(IF 4.686)

Saft C, Leavitt BR, Epplen JT. Clinical utility gene card for: Huntington's disease. Eur J Hum Genet. 2014 May;22(5).
(IF 4.287)

Müller T, Saft C, Andrich J, Harati A. Diadochokinetic movements differ between patients with Huntington's disease and controls. NeuroRehabilitation. 2013;33(4):649-55.
(IF 1.495)

Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D; REGISTRY Investigators of the European Huntington’s Disease Network, Nguyen HP. Collaborator. The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients. PLoS One. 2013 Jul 22;8(7):e68951.
(IF 2.806)

Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington's Disease Network. Collaborator. Suicidal ideation in a European Huntington's disease population. J Affect Disord. 2013 Oct;151(1):248-58.
(IF 3.432)

Kloster E, Saft C, Epplen JT, Arning L. CNR1 variation is associated with the age at onset in Huntington disease. Eur J Med Genet. 2013 Aug;56(8):416-9.
(IF 2.137)

Beste C, Stock AK, Ness V, Hoffmann R, Lukas C, Saft C. A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data. Sci Rep. 2013;3:1797.
(IF 4.259)

Hart EP, Marinus J, Burgunder JM, Bentivoglio AR, Craufurd D, Reilmann R, Saft C, Roos RA; REGISTRY Investigators of the European Huntington's Disease Network. Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease. Mov Disord. 2013 Jul;28(8):1142-5
(IF 7.072)

Stüwe SH, Goetze O, Lukas C, Klotz P, Hoffmann R, Banasch M, Orth M, Schmidt WE, Gold R, Saft CHepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology. 2013 Feb 19;80(8):743-6.
(IF 8.32)

Vittori A, Orth M, Roos RA, Outeiro TF, Giorgini F, Hollox EJ; Registry investigators of the European Huntington's Disease Network. Collaborator. β-Defensin genomic copy number does not influence the age of onset in Huntington's Disease. J Huntingtons Dis. 2013;2(1):107-24.
(IF )

Neeve VC, Samuels DC, Bindoff LA, van den Bosch B, Van Goethem G, Smeets H, Lombès A, Jardel C, Hirano M, Dimauro S, De Vries M, Smeitink J, Smits BW, de Coo IF, Saft C, Klopstock T, Keiling BC, Czermin B, Abicht A, Lochmüller H, Hudson G, Gorman GG, Turnbull DM, Taylor RW, Holinski-Feder E, Chinnery PF, Horvath R. What is influencing the phenotype of the common homozygous polymerase-γ mutation p.Ala467Thr? Brain. 2012 Dec;135(Pt 12):3614-26.
(IF 10.292)

Saft C, Lissek S, Hoffmann R, Nicolas V, Tegenthoff M, Juckel G, Brüne M. Mentalizing in preclinical Huntington's disease: an fMRI study using cartoon picture stories. Brain Imaging Behav. 2013 Jun;7(2):154-62. (IF 3.985) 

HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. Collaborator A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol. 2013 Jan;70(1):25-33.
(IF 10.029)

Beste C, Wascher E, Dinse HR, Saft CFaster perceptual learning through excitotoxic neurodegeneration. Curr Biol. 2012 Oct 23;22(20):1914-7.
(IF 8.851)

Wolf RC, Grön G, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer GB, Orth M. Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness. Hum Brain Mapp. 2012 Sep;33(9):2161-73.
(IF 4.53)

Wolf RC, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer GB, Orth M. Default-mode network changes in preclinical Huntington's disease. Exp Neurol. 2012 Sep;237(1):191-8.
(IF 4.706)

Abdulkadir A, Ronneberger O, Wolf RC, Pfleiderer B, Saft C, Klöppel S. Functional and structural MRI biomarkers to detect pre-clinical neurodegeneration. Curr Alzheimer Res. 2013 Feb;10(2):125-34.
(IF 2.952)

Beste C, Ness V, Lukas C, Hoffmann R, Stüwe S, Falkenstein M, Saft CMechanisms mediating parallel action monitoring in fronto-striatal circuits. Neuroimage. 2012 Aug 1;62(1):137-46.
(IF 5.835)

Enzi B, Edel MA, Lissek S, Peters S, Hoffmann R, Nicolas V, Tegenthoff M, Juckel G, Saft C. Altered ventral striatal activation during reward and punishment processing in premanifest Huntington's disease: a functional magnetic resonance study. Exp Neurol. 2012 May;235(1):256-64.
(IF 4.706)

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG. Collaborator. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012 Mar 6;78(10):690-5.
(IF 8.32)

Kerasnoudis A, Ellrichmann G, Gold R, Saft C. Teaching Video NeuroImages: spinal and bulbar muscular atrophy mimicking essential tremor. Neurology. 2012 Feb 7;78(6):e41.
(IF 8.32)

Föller M, Hermann A, Gu S, Alesutan I, Qadri SM, Borst O, Schmidt EM, Schiele F, vom Hagen JM, Saft C, Schöls L, Lerche H, Stournaras C, Storch A, Lang F. Chorein-sensitive polymerization of cortical actin and suicidal cell death in chorea-acanthocytosis. FASEB J. 2012 Apr;26(4):1526-34.
(IF 5.498)

Cubo E, González M, del Puerto I, de Yébenes JG, Arconada OF, Gabriel y Galán JM; European Huntington's Disease Initiative Study Group. Collaborator. Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease. Mov Disord. 2012 Mar;27(3):439-42.
(IF 7.072)

Saft C, Andrich J, Fälker M, Gauda S, Küchler S, Woitalla D, Goetze O. No evidence of impaired gastric emptying in early Huntington's Disease. PLoS Curr. 2011 Oct 25;3:RRN1284.
(IF )

Stüwe SH, Goetze O, Arning L, Banasch M, Schmidt WE, Schöls L, Saft CHepatic mitochondrial dysfunction in Friedreich ataxia. BMC Neurol. 2011 Nov 15;11:145.
(IF 2.006)

de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J; MermaiHD study investigators. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011 Dec;10(12):1049-57.
(IF 26.284)

Saft C, Epplen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D; REGISTRY Investigators of the European Huntington's Disease Network, Arning L. NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLoS Curr. 2011 Oct 4;3:RRN1247.
(IF )

Beste C, Schüttke A, Pfleiderer B, Saft C. Music perception and movement deterioration in Huntington's disease. PLoS Curr. 2011 Sep 20;3:RRN1252.
(IF )

Beste C, Ness V, Falkenstein M, Saft C. On the role of fronto-striatal neural synchronization processes for response inhibition—evidence from ERP phase-synchronization analyses in pre-manifest Huntington's diseasegene mutation carriers. Neuropsychologia. 2011 Oct;49(12):3484-93.
(IF 3.197)

Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington’s Disease Network. Collaborator Discrepancies in reporting the CAG repeat lengths for Huntington's disease. Eur J Hum Genet. 2012 Jan;20(1):20-6.
(IF 4.287)

Taherzadeh-Fard E*, Saft C*, Akkad DA, Wieczorek S, Haghikia A, Chan A, Epplen JT, Arning L. PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease. Mol Neurodegener. 2011 May 19;6(1):32. *contributed equally
(IF 6.78)

Wolf RC, Grön G, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer GB, Orth M. Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. J Cereb Blood Flow Metab. 2011 Sep;31(9):1908-18.
(IF 5.081)

Saft C, Reber D, Streuer M, Andrich J. Post pump chorea in a 77-year-old male. Neurol Sci. 2011 Aug;32(4):699-701.
(IF 1.749)

Brüne M, Blank K, Witthaus H, Saft C"Theory of mind" is impaired in Huntington's disease. Mov Disord. 2011 Mar;26(4):671-8.
(IF 7.072)

Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C, Gold R, Linker RA. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One. 2011 Jan 31;6(1):e16172.
(IF 2.806)

Krogias C, Strassburger K, Eyding J, Gold R, Norra C, Juckel G, Saft C*, Ninphius D*. Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. *contributed equally J Psychiatry Neurosci. 2011 May;36(3):187-94.
(IF 5.165)

Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB. Collaborator Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1409-12.
(IF 7.349)

Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB; Investigators of the European Huntington's Disease Network. Collaborator Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. Version 2. PLoS Curr. 2010 Sep 28
(IF )

Taherzadeh-Fard E, Saft C, Wieczorek S, Epplen JT, Arning L. Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics. 2010 Oct;11(4):435-9.
(IF 3.269)

Arning L, Haghikia A, Taherzadeh-Fard E, Saft C, Andrich J, Pula B, Höxtermann S, Wieczorek S, Akkad DA, Perrech M, Gold R, Epplen JT, Chan A. Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med (Berl). 2010 Apr;88(4):431-6.
(IF 5.004)

Henley SM, Ridgway GR, Scahill RI, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J; EHDN Imaging Working Group. Collaborator. Pitfalls in the use of voxel-based morphometry as a biomarker: examples from huntington disease. AJNR Am J Neuroradiol. 2010 Apr;31(4):711-9.
(IF 3.55)

Beste C, Willemssen R, Saft C, Falkenstein M. Response inhibition subprocesses and dopaminergic pathways: basal ganglia disease effects. Neuropsychologia. 2010 Jan;48(2):366-73.
(IF 3.197)

Aziz NA, Jurgens CK, Landwehrmeyer GB; EHDN Registry Study Group, van Roon-Mom WM, van Ommen GJ, Stijnen T, Roos RA. Collaborator. Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology. 2009 Oct 20;73(16):1280-5.
(IF 8.32)

Andrich JE, Wobben M, Klotz P, Goetze O, Saft CUpper gastrointestinal findings in Huntington's disease: patients suffer but do not complain. J Neural Transm. 2009 Dec;116(12):1607-11.
(IF 2.392)

Taherzadeh-Fard E, Saft C, Andrich J, Wieczorek S, Arning L. PGC-1alpha as modifier of onset age in Huntington disease Mol Neurodegener. 2009 Feb 6;4:10.
(IF 6.78)

Beste C, Willemssen R, Saft C, Falkenstein M. Error processing in normal aging and in basal ganglia disorders. Neuroscience. 2009 Mar 3;159(1):143-9.
(IF 3.277)

Beste C, Konrad C, Saft C, Ukas T, Andrich J, Pfleiderer B, Hausmann M, Falkenstein M. Alterations in voluntary movement execution in Huntington's disease are related to the dominant motor system - Evidence from event-related potentials. Exp Neurol. 2009 Mar;216(1):148-57.
(IF 4.706)

Beste C, Saft C, Güntürkün O, Falkenstein M. Increased cognitive functioning in symptomatic Huntington's disease as revealed by behavioral and event-related potential indices of auditory sensory memory and attention. J Neurosci. 2008 Nov 5;28(45):11695-702.
(IF 5.988)

Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RA; EHDI Study Group. Collaborator. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology. 2008 Nov 4;71(19):1506-13.
(IF 8.32)

Arning L, Monté D, Hansen W, Wieczorek S, Jagiello P, Akkad DA, Andrich J, Kraus PH, Saft C, Epplen JT. ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease. J Mol Med. 2008 Apr;86(4):485-90.
(IF 5.004)

Andrich J, Arning L, Wieczorek S, Kraus PH, Gold R, Saft C. Huntington's disease as caused by 34 CAG repeats. Mov Disord. 2008 Feb 28;23(6):879-881
(IF 7.072)

Beste C, Saft C, Andrich J, Gold R, Falkenstein M. Response inhibition in Huntington's disease-A study using ERPs and sLORETA. Neuropsychologia. 2008;46(5):1290-1297.
(IF 3.197)

Saft C, Schüttke A, Beste C, Andrich J, Heindel W, Pfleiderer B. fMRI reveals altered auditory processing in manifest and premanifest Huntington's disease. Neuropsychologia. 2008;46(5):1279-89.
(IF 3.197)

Beste C, Saft C, Andrich J, Gold R, Falkenstein M. Stimulus-response compatibility in Huntington's disease: a cognitive-neurophysiological analysis. J Neurophysiol. 2008 Mar;99(3):1213-23.
(IF 2.396)

Beste C, Saft C, Andrich J, Müller T, Gold R, Falkenstein M Time processing in Huntington’s disease: a Group Control Study PLoS ONE. 2007 Dec 5;2(12):e1263
(IF 2.806)

Beste C*, Saft C*, Yordanova J, Andrich J, Gold R, Falkenstein M, Kolev V. Functional compensation or pathology in cortico-subcortical interactions in preclinical Huntington's disease? Neuropsychologia. 2007 Jul 2;45(13):2922-30. *contributed equally
(IF 3.197)

Arning L, Saft C, Wieczorek S, Andrich J, Kraus PH, Epplen JT. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet. 2007 Sep;122(2):175-82.
(IF 4.637)

Beste C*, Saft C*, Konrad C, Habbel A, Schepers I, Jansen A, Pfleiderer B, Falkenstein M Levels of error processing in Huntington´s Disease: a combined study using event-related potentials and voxel-based morphometry. Hum Brain Mapp 2008 Feb;29(2):121-30.*contributed equally
(IF 4.53)

Andrich J, Saft C, Ostholt N, Müller T Assessment of simple movements and progression of Huntington‘s Disease J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):405-7.
(IF 7.349)

Andrich J, Saft C, Ostholt N, Müller T Complex movement behaviour and progression of Huntington‘s Disease Neurosci Lett. 2007 Apr 18;416(3):272-4.
(IF 2.18)

Beste C*, Saft C*, Andrich J, Gold R, Falkenstein M. Error Processing in Huntington's Disease. PLoS ONE. 2006 Dec 20;1(1):e86 *contributed equally
(IF 2.806)

Pechlivanis I, Andrich J, Scholz M, Harders A, Saft C, Schmieder K Chronic subdural haematoma in patients with Huntington's disease Br J Neurosurg. 2006 Oct;20(5):327-9.
(IF 1.051)

Mai M, Akkad AD, Wieczorek S, Saft C, Andrich J, Kraus PH, Epplen JT, Arning L. No association between polymorphisms in the BDNF gene and age at onset in Huntington disease. BMC Med Genet. 2006 Nov 10;7(1):79.
(IF 2.198)

Bauer P, Kreuz FR, Burk K, Saft C, Andrich J, Heilemann H, Riess O, Schols L. Mutations in TITF1 are not relevant to sporadic and familial chorea of unknown cause. Mov Disord. 2006 Oct;21(10):1734-7.
(IF 7.072)

Saft C, Andrich J, Meisel NM, Przuntek H, Müller T Assessment of simple movements reflects impairment in Huntington‘s Disease Mov Disord. 2006 Aug;21(8):1208-12
(IF 7.072)

Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. BMC Neurol. 2006 Feb 28;6(1):11
(IF 2.006)

Hansen W, Saft C, Andrich J, Muller T, Wieczorek S, Epplen JT, Arning L. Failure to confirm influence of Methyltetrahydrofolate reductase (MTHFR) polymorphisms on age at onset of Huntington disease. J Negat Results Biomed. 2005 Dec 22;4(1):12
(IF )

Squitieri F, Cannella M, Sgarbi G, Maglione V, Falleni A, Lenzi P, Baracca A, Cislaghi G, Saft C, Ragona G, Russo MA, Thompson LM, Solaini G, Fornai F. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev. 2006 Feb;127(2):217-20.
(IF 3.087)

Petrasch-Parwez E, Saft C, Schlichting A, Andrich J, Napirei M, Arning L, Wieczorek S, Dermietzel R, Epplen JT. Is the retina affected in Huntington disease?Acta Neuropathol (Berl). 2005 Nov;110(5):523-5.
(IF 12.213)

Saft C, Andrich J, Kraus PH, Przuntek H. Der Einsatz von Amisulprid bei Patienten mit M. Huntington Psychiatr Prax. 2005 Oct;32(7):363-6.
(IF 1.302)

Arning L, Kraus PH, Saft C, Andrich J, Epplen JT. Age at onset of Huntington disease is not modulated by the R72P variation in TP53 and the R196K variation in the gene coding for the human caspase activated DNase (hCAD). BMC Med Genet. 2005 Oct 3;6(1):35
(IF 2.198)

Arning L, Kraus PH, Valentin S, Saft C, Andrich J, Epplen JT. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics. 2005 Feb;6(1):25-8. Epub 2004 Nov 17.
(IF 3.269)

Saft C, Zange J, Andrich J, Müller K, Lindenberg K, Landwehrmeyer B, Vorgerd M, Kraus PH, Przuntek H, Schöls L. Mitochondrial impairment in patients and asymptomatic gene carriers of Huntington's disease. A magnetic resonance spectroscopy study Mov Disord. 2005 Jun;20(6):674-9.
(IF 7.072)

Saft C, Andrich J, Przuntek H, Müller T, Stücker M Segmentale Schweißsekretionsstörung bei MSA [Segmental dysfunction of sweating in multiple system atrophy.] Hautarzt. 2005 Aug;56(8):773-777.
(IF 0.661)

Saft C, Andrich J, Neuen-Jacob E, Schmid G, Schols L, Amoiridis G Supracubital perineurioma of the median nerve misdiagnosed as carpal tunnel syndrom BMC neurology 2004, 4:19
(IF 2.006)

Saft C, Andrich J, Brune N, Gencik M, Kraus PH, Przuntek H, Epplen JT Apolipoprotein E genotypes do not influence the age of onset in Huntington´s disease J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1692-1696
(IF 7.349)

Andrich J, Saft C, Gerlach M, Schneider B, Arz A, Kuhn W, Müller T. Coenzyme Q10 levels in Huntington‘s Disease J Neural Transm Suppl. 2004;(68):111-6.
(IF 1.071)

Brune N, Andrich J, Gencik M, Saft C, Müller T, Valentin S, Przuntek H, Epplen JT MTHFR Polymorphisms in Huntington‘s Disease J Neural Transm Suppl. 2004;(68):105-10.
(IF 1.071)

Saft C, Andrich J, Meisel NM, Przuntek H, Müller T Congruent deteriation of complex and simple movements in patients with Huntington‘s Disease J Neural Transm Suppl. 2004;(68):97-104.
(IF 1.071)

Arning L, Jagiello P, Wieczorek S, Saft C, Andrich J, Epplen JT. Glutathione S-Transferase Omega 1 variation does not influence age at onset of Huntington's disease. BMC Med Genet. 2004 Mar 24;5(1):7.
(IF 2.198)

Andrich J, Saft C, Arz A, Schneider B, Agelink MW, Kraus PH, Kuhn W, Muller T. Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD. Mov Disord. 2004 Feb;19(2):226-8.
(IF 7.072)

Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, Ecker D, Andrich J, Saft C, Kraus P, Aschoff AJ, Ludolph AC, Landwehrmeyer GB. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):213-20.
(IF 7.349)

Saft C, Andrich J, Meisel NM, Przuntek H, Muller T. Assessment of complex movements reflects dysfunction in Huntington's disease. J Neurol. 2003 Dec;250(12):1469-74.
(IF 3.389)

Saft C, Andrich J, Stücker M, Przuntek H, Müller T. Asymmetric anhidrosis in MSA. Neurology. 2003 Jul 22;61(2):231.
(IF 8.32)

Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT, Przuntek H, Agelink MW. Autonomic nervous system function in Huntington's disease. J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):726-31.
(IF 7.349)

Müller T, Woitalla D, Saft C, Kuhn W. Levodopa in plasma correlates with body weight of parkinsonian patients Parkinsonism Relat Disord. 2000 Jul 1;6(3):171-173.
(IF 4.484)

 

Not Medline listed:

Beste C, Schüttke A, Konrad C, Saft C, Andrich J, Pfleiderer B Functional connectivity during auditory processing in Huntington’s Disease The Journal of Psychophysiology. Volume 22, Number 4 / 2008, 195-201
(IF 1.683)

Coenzym Q10 ohne neuroprotektiven Effekt Saft C, InFo Neurologie & Psychiatrie, 2017
(IF )

Modifiziertes Tetrabenazin verbessert Chorea (mit Kommentar) Saft C, InFo Neurologie & Psychiatrie, October 2016, Volume 18, Issue 10, pp 31–31
(IF )

Guidelines "Chorea/Huntington Disease" for the German-Speaking Countries Revised. Saft, Carsten; Bonelli, Raphael M.; Burgunder, Jean-Marc; et al. Akt Neurol, Volume: 45   Issue: 8   Pages: 570-585
(IF 0.32)

Guidelines "Chorea/Huntington Disease" for the German-Speaking Countries Revised.  Saft, Carsten; Bonelli, Raphael M.; Burgunder, Jean-Marc; et al. Akt Neurol, Volume: 45   Issue: 8   Pages: 570-585
(IF 0.32)

Aggressive Subgruppe erfordert Reklassifikation. Saft C, InFo Neurologie & Psychiatrie, Dez 2018, 20 (12), 2
(IF )

 

Reviews (Medline listed):

Epplen JT, Gencik M, Epplen A, Andrich J, Saft C, Przuntek H. Morbus Huntington – a human genetic model disease Cytogenet Cell Genet. [heute: Cytogenetic Genome Res.] 2000;91(1-4):90-6.
(IF 1.162)

Ellrichmann G, Reick C, Saft C, Linker RA. The role of the immune system in Huntington's disease. Clin Dev Immunol. 2013;2013:541259.
(IF 3.603)

 

Reviews (Not Medline listed):

Saft C, Kosinski C, Landwehrmeyer GB Fortschritte in Früh- und Verlaufsdiagnostik bei Morbus Huntington Akt Neurol. 01/2009; 36(10):506-523.
(IF 0.32)

Susmuth SD, Saft C, Reilmann R, Orth M, Landwehrmeyer GB Was gibt es Neues bei der Huntington-Krankheit? Huntington’s disease update Akt Neurol 2013; 40: 377–392
(IF 0.32)

Books

Saft C, Bär KJ, Bonelli RM, Burgunder JM, Dose M, Epplen JT, Jung HH, Kosinski C, Landwehrmeyer GB, Priller J, Reilmann R, Seppi K, Töpper R, Federführender Autor der Leitlinien Chorea / Morbus Huntington der DGN, DGPPN und GfH Leitlinien für Diagnostik und Therapie in der Neurologie. Leitlinien Chorea / Morbus Huntington

Amygdala (ISBN 980-953-307-188-1) Chapter title: The ventral striatopallidum and extended amygdala in Huntington Disease Petrasch-Parwez E, Habbes HW, Löbbecke-Schumacher M, Saft C and Niescery J 

Saft C. et al. S2k-Leitlinie Chorea/Morbus Huntington. 2017. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien

SOPs Neurologie. Herausgeber: Gereon Rudolph Fink, Ralf Gold, Peter Berlit. 2018. 564 Seiten, 119 Abb. ISBN: 9783132411128. Thieme Verlag. Chapter „Chorea“, Carsten Saft, page 171-174

Talks (Selection):

Morbus Huntington – prädiktive Diagnostik, medizinische und psychosoziale Betreuung von Patienten und Risikopersonen. „Klinik des M. Huntington mit Präsentation von Fallbeispielen – warum braucht man ein spezielles Zentrum?  Vortrag im Rahmen der ärztlichen Fortbildung, auf Einladung, Fortbildungszentrum der LÄK Hessen, Bad Nauheim, 29.09.2001

Huntington patients presented altered habituation in the auditory cortex as measured by fMRI Euro-HD, Joint Working Group Meeting Biomarker and Imaging in Lund, Schweden, 12.-13.05.2006.

Chorea – Vorstellung der eigenen Forschergruppe 7.-10-03.20075. Deutscher Parkinsonkongress, Ulm

Educational Seminar Morbus Huntington 37th Int. Danube Symposium for Neurological Science and Continuing Education., 1th
International Congress on ADHD 04.-05.06.2007, Würzburg

Huntington’s disease as caused by 3¬4 CAG repeats. 21th International Meeting of the World Federation of Neurology Research Group of
Huntington Disease, 09.-11.09.2007, Dresden, Germany

Modifier-Gene und Biomarker bei Morbus Huntington 1. Neurogenetik Symposium, St. Josef Hospital Bochum 09.02.2008, Fortbildungsveranstaltung der ÄKWL

Neue Erkenntnisse zur funktionellen Frühdiagnostik bei M. Huntington. Frühe funktionelle Veränderungen und ihre klinischen Konsequenzen bei
präsymptomatischen Mutationsträgern für M. Huntington. Chair. 11.09.2008, 81. Kongress der DGN, Hamburg, Minisymposium

Hyperkinetische Bewegungsstörungen. 6. Neurologisch – Psychiatrisches Kolloquium, Temmler ZNS. 17.-18.10.2008. Weimar

M. Huntington. Neurologie Symposium. Marien-Hospital Euskirchen, Dr. med. Bauer, Temmler ZNS. 22.10.2008. Euskirchen

M. Huntington. Parkinson – Kongress Marburg. Sateliten-Symposium Temmler Pharama ZNS. 06.03.2009. Marburg

M. Huntington – Frühdiagnosik, Modifier, Therapie und Differentialdiagnostik. Vortragsreihe der Neurologischen Klinik Minden – Prof. Röther.
01.04.2009. Minden

Hyperkinetische Bewegungsstörungen. Psychiatrisches Kolloquium, Temmler ZNS. 25.11.2008. Siegen

Biomarker bei HD; 27.02.10; 15 Jahre HZ NRW; Bochum

M. Huntington – Biomarker, Phänotypen und Differentialdiagnosen, Düsseldorf, Laborseminar Institut für Klinische Neurowissenschaften, Univ.- Prof. Dr. A. Schnitzler, Auf Einladung. 25.03.2010.

Update - M. Huntington. 02.02.2011, Neurologie Fortbildungsveranstaltungen im St. Marien-Hospital, Lünen

Update - M. Huntington. Parkinson – Kongress Kiel. Sateliten-Symposium Temmler Pharama ZNS. Auf Einladung. 11.03.2011. Kiel

Non invasive 13C methionine breath test (MeBT) as a marker for hepatic mitochondrial dysfunction in premanifest Huntington´s Disease Results from a 15 month follow up in 25 mutation carriers EHDN Biomarker Working Group Meeting, Nov 1th 2013, Frankfurt, Germany

A novel cognitive neurophysiological state biomarker in premanifest HD EHDN Biomarker Working Group Meeting, Nov 1th 2013, Frankfurt, Germany

Differentialdiagnosen und Therapie choreatiformer Bewegungsstörungen. Neurologische Fortbildung Universitätsklinikum Knappschaftskrankenhaus Bochum, Prof. Schlegel. 13.11.2012

M. Huntington – update Therapie und Differentialdiagnose / aktuelle Studien und Forschungsansätze / Vortrag mit Videobeispielen
Ökomenisches Hainich Klinikum gGmbH, Prof . M. Jauß, 30.01.2013

M. Huntington. Therapie und laufende Studien – ein Update Wissenschaftliches Symposium für Mediziner und alle Interessierten
anlässlich des 20 – jährigen Bestehens des Huntington – Zentrums NRW, Bochum, 29. März 2014

Neurologische Klinik, RWTH Aachen, Direktor: Univ.-Prof. Dr. J. Schulz., Gemeinsame Veranstaltung der Klinik für Neurologie, Klinik für Neurochirurgie, Klinik für Neuroradiologie und Institut für Neuropathologie. Neurowissenschaftliches Seminar. Sommersemester 2014, Dienstag, 06.05.2014, Update M. Huntington – Differential-diagnosen und Therapieansätze.

Bewegungsstörungen. Differentialdiagnose und Therapie der Chorea Huntington. Wermsdorf, Fachkrankenhaus Hubertusburg, 06.09.2014

Morbus Huntington - Beispiel für eine vererbte neurologische Erkrankung Brain Day 2014, 10.09.2014, Ruhr-Uni-Bochum, Sonderforschungsbereich 874, Integration und Repräsentation sensorischer Prozesse Hamburg, Fachgespräche Huntington, 18.10.2014, Desitin.

Choreatiforme Bewegungsstörungen. Videoseminar. DGN - Jahreskongress 2014 in München. 18.09.2014.

Hamburg, Fachgespräche Huntington, 18.10.2014, Desitin.

M. Huntington, Qualitätszirkel Oberhausen. Temmler. 24.03.2015

Das klinische Spektrum der Huntington Krankheit. 9. Deutscher Parkinsonkongress. 17.April.2015, Berlin

Universitätsklinikum der RWTH Aachen, Huntington-Symposium, 25.04.2015, Aachen, Leitliniengerechte pharmakologische Therapie

Expertenworkshop Huntington und Depression, Desitin Hamburg, 12.06.2015.

Hyperkinetische Bewegungsstörungen im Dialog. Erding. Huntington Zentrum Süd, 18.09.2015

M. Huntington – ein update. Krankenhaus St. Franziskus, Mönchengladbach, Prof. Carl-Albrecht Haensch, 30.09.2015

DGN Minisymposium, Die Huntington-Krankheit eine neuropsychiatrische Herausforderung neue Einsichten und Therapien in Entwicklung, 26.09.2015 (Vorsitz: Saft / Landwehrmeyer)

Neue Entwicklungen bei Morbus Huntington. Intensivseminar Karlsruhe. Prof. Gahn. 21.11.2015

Bewegungsstörungen im Dialog, Huntington, 09.April.2016 Köln. Intensiv-Fortbildung, Desitin

DGN-Symposium Neue therapeutische Targets bei Neurodegeneration C Saft: From Bench to bedside – aktuelle Studienlage bei Morbus Huntington
89. Kongress der DGN: 21. bis 24. September 2016 in Mannheim

M. Huntington: Differentialdiagnose, Therapie, aktuelle Studien C. Saft Dresdener Neurologisches Herbstsymposium 2016, 5.Nov.2016

M. Huntington: Therapie, aktuelle Studien, Differentialdiagnose Universität Kiel, Neurologie, Frau Prof D Berg auf Einladung, 25.01.2017

M. Huntington: Therapie, aktuelle Studien, Differentialdiagnose TEVA 18. Februar 2017 Ärzte-Fortbildung, Bad Neuenahr

Genet(h)ik für den Menschen. Veranstaltung für 1400 Oberstufenschüler anlässlich der 28. Jahrestagung der DfH. C Saft und L Rey. Wissen oder nicht Wissen?
Genetische Testung am Beispiel der Huntington-Erkrankung. Audimax Ruhr-Uni-Bochum, 29.März.2017

M. Huntington: Therapie, aktuelle Studien, Differentialdiagnose Neuroforum, Prof. Dr. Jens Volkmann auf Einladung, Neurologie Universität Würzburg, 10.05.2017

Tardive Dyskinesien Experten Meeting Overview national situation regarding TD treatment AOP Orphan Pharmaceuticals AG 8. Oktober 2017 Titanic Hotel Berlin

Symptomatische Behandlung der Huntington-Krankheit 14.04.2018 „20 Jahre Huntington-Zentrum-Süd Isar-Amper-Klinikum Taufkirchen

Essener Bewegungsstörungssymposium, 09.06.29018 Saalbau Essen, Chorea Huntington – ein Update, Universitätsklinik Essen.

Leitlinien der Behandlung der Huntington-Krankheit. Stand der Forschung 08.09.2018 „20 Jahre Huntington-Zentrum Nord“, Heiligenhafen

Management of HD Symptoms, Carsten Saft (Bochum, Germany), Klaus Seppi (Innsbruck, Austria), Sunday, September 16th, 2018, Breakfast teaching courses
EHDN Plenary Meeting, Austria Center Vienna in Vienna, Austria, 14-16 September 2018

"Update Huntington" Knappschaftskrankenhaus, Ruhr-Universität Bochum, 27.11.2018

Meet the Expert. Aktuelle Studien bei Morbus Huntington/Antisense und andere, C. Saft (Bochum), S. M. von Hein (Bochum) Neurowoche 2018, 30. Oktober – 3. November 2018, Berlin (Messe Berlin), 91. Kongress der Deutschen Gesellschaft für Neurologie, 2018

Differentialdiagnose der Chorea - interaktives Seminar mit Videobeispielen. FS-16 Vorsitz Carsten Saft, Bochum Deutscher Kongress für Parkinson und Bewegungsstörungen. 7. – 9. März 2019, Düsseldorf 08.03.2019

Aktuelle Leitliniengerechte Therapie und erste Antisense – Ergebnisse. 002 Morbus Huntington - ein Update. Vorsitz. Carsten Saft, S24.
Deutscher Kongress für Parkinson und Bewegungsstörungen. 7. – 9. März 2019, Düsseldorf, 08.03.2019